Article
Immunology
Wentao Zhang, Haizeng Qu, Xiaoqing Ma, Liang Li, Yanjun Wei, Ye Wang, Renya Zeng, Yuanliu Nie, Chenggui Zhang, Ke Yin, Fengge Zhou, Zhe Yang
Summary: This study aimed to create a survival prediction model for lung adenocarcinoma patients based on cuproptosis and immune-related genes, which can enhance personalized treatment. Through RNA sequencing analysis, key genes related to cuproptosis and immune response were identified, and a risk prognostic model was developed. The results showed significantly reduced survival rates in the high-risk group, along with lower levels of immune cell infiltration and immune checkpoint expression.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Tao Yang, Lizheng Hao, Renyun Cui, Huanyu Liu, Jian Chen, Jiongjun An, Shuo Qi, Zhong Li
Summary: The study aimed to identify a potential signature model to improve prognosis of lung adenocarcinoma. Through analyzing genomic data and immune scores, the study predicted patients' overall survival rates and found that high stromal and immune scores were associated with better survival rates, effectively classifying different risk groups.
Article
Biochemistry & Molecular Biology
Long Tian, Yan Wang, Jie Tian, Wenpeng Song, Lu Li, Guowei Che
Summary: This study investigates the correlation between m6A/m5C regulated genes and early-stage lung adenocarcinoma (LUAD). Two subtypes, Cluster1 and Cluster2, show significantly different prognostic outcomes. Cluster1 has a better prognosis and is characterized by an inflammatory immune subtype, low immune infiltration, and high MHC expression. Cluster2 shows a T cell exhaustion state and high tumor mutational burden, along with numerous mutated oncogene and tumor suppressor genes. A seven-gene risk model is constructed and validated to assess the prognosis of early-stage LUAD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Ran Chen, Haichao Luo, Qitian Chen, Changying Wang
Summary: This study aimed to construct a prognosis model for lung adenocarcinoma (LUAD) using cuproptosis-related long non-coding RNA (lncRNA). The model was tested for its prognostic value and its correlation with tumor immunity and mutation burden. It also predicted potentially sensitive drugs for LUAD patients.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Shouzheng Ma, Jun Zhu, Mengmeng Wang, Jianfei Zhu, Wenchen Wang, Yanlu Xiong, Runmin Jiang, Nagarashee Seetharamu, Fernando Conrado Abrao, Vinayaga Moorthi Puthamohan, Lei Liu, Tao Jiang
Summary: Using RNA sequencing data, researchers established a prognostic signature of copper-related lncRNAs that can effectively predict the prognosis and therapeutic responses of lung adenocarcinoma patients. This signature may serve as a novel biomarker and therapeutic target for lung adenocarcinoma.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Review
Medicine, General & Internal
Huang Di, Jiting Zhao, Xue Zhu, Xinpeng Zhou, Yuanlong Hu, Mengjie Wang, Zhanjun Qiu, Wei Zhang, Xianhai Chen
Summary: This study identified cuproptosis-related lncRNAs (CRlncRNAs) through co-expression analysis and constructed a risk prognostic model using Cox and LASSO regression analyses. The novel prognostic signature based on CRlncRNAs effectively assessed and predicted the prognosis of lung adenocarcinoma (LUAD) patients, providing a new perspective for diagnosis and treatment.
Article
Oncology
Zhou Jiang, Yongzhong Luo, Lemeng Zhang, Haitao Li, Changqie Pan, Hua Yang, Tianli Cheng, Jianhua Chen
Summary: The study revealed that lactate metabolism-associated genes were significantly associated with OS and immune signatures in LUAD, and a risk scoring model constructed by analyzing these genes could effectively predict patient survival and was correlated with the outcome of anti-PD-1/L1 therapy.
Article
Oncology
Aisha Al-Dherasi, Qi-Tian Huang, Yuwei Liao, Sultan Al-Mosaib, Rulin Hua, Yichen Wang, Ying Yu, Yu Zhang, Xuehong Zhang, Chao Huang, Haithm Mousa, Dongcen Ge, Sufiyan Sufiyan, Wanting Bai, Ruimei Liu, Yanyan Shao, Yulong Li, Jingkai Zhang, Leming Shi, Dekang Lv, Zhiguang Li, Quentin Liu
Summary: This study established a prognostic signature consisting of seven genes related to overall survival in LUAD patients. The signature effectively categorized patients into high and low-risk groups and showed good predictive performance in both training and validation cohorts.
CANCER CELL INTERNATIONAL
(2021)
Article
Biotechnology & Applied Microbiology
Zhaofei Pang, Xiaowei Chen, Yu Wang, Yadong Wang, Tao Yan, Jun Wan, Kai Wang, Jiajun Du
Summary: This study explored the synergistic and antagonistic effects of tumor microenvironment and tumor mutation pattern on lung adenocarcinoma. A 14-lncRNA immune-related signature, with C5orf64 identified as a potential indicator for TME modulation and tumor mutation pattern remodeling, was developed through analysis of immune-related genes and construction of a ceRNA network. High expression of PD-1, PD-L1 and CTLA-4 was demonstrated in high-level C5orf64 groups, while a negative correlation was observed between C5orf64 and TP53 mutation frequency. A novel model based on age, tumor stage and immune-related lncRNA signature was proposed.
Article
Immunology
Mingchuang Zhu, Qingpeng Zeng, Tao Fan, Yuanyuan Lei, Feng Wang, Sufei Zheng, Xinfeng Wang, Hui Zeng, Fengwei Tan, Nan Sun, Qi Xue, Jie He
Summary: This study presents a novel lipid metabolism-based signature for predicting recurrence in early-stage LUAD, providing important guidance for optimizing immunotherapy or chemotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xiaodong Ling, Luquan Zhang, Chengyuan Fang, Hao Liang, Jinhong Zhu, Jianqun Ma
Summary: This study identified a gene set related to copper-induced cell death in lung adenocarcinoma and constructed a prognostic risk model consisting of 7 genes. The model can predict the survival risk of patients with lung adenocarcinoma and improve the development of personalized treatment strategies.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Genetics & Heredity
Yufei Wang, Chen Zhang, Chengyue Ji, Wenli Jin, Xin He, Shunzhi Yu, Renhua Guo
Summary: Recent studies have identified different molecular subtypes of LUAD associated with cuproptosis-related genes, showing different prognoses. Patients with high cuproptosis scores had higher somatic mutation frequency and stemness scores, while patients with low cuproptosis scores had more immune infiltration and better prognosis. The cuproptosis score may serve as a promising biomarker to guide immunotherapy in LUAD.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Xiaoqing Ma, Zilin Deng, Zhen Li, Ting Ma, Guiqing Li, Cuijia Zhang, Wentao Zhang, Jin Chang
Summary: By analyzing multiple data sources including RNA sequencing data, we have identified four disulfidptosis/ferroptosis-related genes that are associated with the prognosis of lung adenocarcinoma. We have constructed a robust prognostic model and found that the high-risk group has significantly lower overall survival compared to the low-risk group.
CANCER CELL INTERNATIONAL
(2023)
Article
Genetics & Heredity
Prithvi Singh, Shweta Arora, Amjad Beg, Sibasis Sahoo, Arnab Nayek, Mohd Mabood Khan, Anuradha Sinha, Zubbair Malik, Fareeda Athar, Mohammad Serajuddin, Ravins Dohare, Mansoor Ali Syed
Summary: The study found that ANLN is highly expressed in lung adenocarcinoma and is associated with tumor progression and survival. High-throughput screening and molecular docking showed that kaempferol strongly interacts with the active site of ANLN and acts as a potential tumor inhibitor. This study provides insights into the interaction between ANLN and kaempferol, and identifies a potential natural compound with anticancer effects.
FUNCTIONAL & INTEGRATIVE GENOMICS
(2023)
Article
Medicine, General & Internal
Ankang Hu, Kaicheng Tang, Jing Liu, Xufeng Han, Quangang Chen
Summary: In this study, the expression of PRR11 in various cancers was analyzed based on TCGA database, and its prognostic value in LUAD was explored using GEPIA2 database. The association between PRR11 and clinicopathological features of LUAD was also examined. The results showed that high expression of PRR11 was associated with poor survival outcomes in LUAD patients and correlated with several clinicopathological features. Additionally, PRR11 expression was related to immune infiltration in the tumor microenvironment.